Anebulo Pharmaceuticals, Inc.

ANEB

Explore Our Financial Data > Companies > Anebulo Pharmaceuticals, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
ANEB
CIK0001815974
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

AddressJFL CAPITAL MANAGEMENT, 1017 RR 620 S, SUITE 107, LAKEWAY, TX, 78734
Website anebulo.com
Phone737 203 5270
CEOSimon Allen
Employees4

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
RevenueN/A
Pre-Tax Income$-7.69 million
Net Income$-7.69 million
Net Income to Common$-7.69 million
EPS$-0.26
View All
Balance Sheet
Cash$13.28 million
Assets$14.01 million
Liabilities$546,032.00
Common Equity$13.46 million
Liabilities & Equity$14.01 million
View All
Cash Flow Statement
Net Income$-7.69 million
Cash From Operating Activities$-6.75 million
Cash From Investing ActivitiesN/A
Cash From Financing Activities$14.88 million
Change in Cash$8.13 million
View All
Calculations
NOPAT$-5.76 million
EBITDA$-7.03 million
Price to EarningsN/A
Price to Book$8.70
ROE-83.37%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Cannabis Use Disorder (CUD) Pipeline Market Research Report 2025 Featuring Aelis Farma, Anebulo Pharmaceuticals, and Indivior

The "Cannabis Use Disorder (CUD) - Pipeline Insight, 2025" report provides an in-depth analysis of the CUD pipeline, featuring over 5 companies and drugs in development, including Aelis Farma's AEF0117. It covers drug profiles, novel therapies, therapeutic assessments, and emerging trends to address CUD challenges.Dublin, July 25, 2025 (GLOBE NEWSWIRE) -- The "Cannabis Use Disorder (CUD) - Pipeline Insight, 2025" has been added to ResearchAndMarkets.com's offering. The report offers an in-depth

Article Link

Top Midday Gainers

Abivax (ABVX) shares catapulted 555% amid heavy trading after the company said late Tuesday its inve

Article Link

Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock

AUSTIN, Texas, July 23, 2025--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced that a Special Committee of independent directors has recommended, and its Board of Directors (the "Board") has approved, as part of a going private transaction, a reverse stock split at a ratio of not less than 1-for-2,500 and not greater than 1-f

Article Link

Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates

AUSTIN, Texas, May 13, 2025--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic effects (the "Company" or "Anebulo"), today announced financial results for the three months ended March 31, 2025, and recent updates.

Article Link

Here's Why We're Not Too Worried About Anebulo Pharmaceuticals' (NASDAQ:ANEB) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Article Link